Lars Rosendal joined UNION in August 2024 as Chief Development Officer. Lars brings more than 15 years of experience from the pharmaceutical industry, where he has held several leadership positions.
Prior to joining UNION, Lars was VP and head of Global Clinical Operation at LEO Pharma. In this role Lars was responsible for delivering 8 Phase 3 studies on Adtralza®/Adbry® (tralokinumab) in parallel and successfully bringing Anzupgo® (delgocitinib) through global development and Enstilar® through development in China. Lars has extensive experience within immunology and dermatology, in particular atopic dermatitis (AD), chronic hand eczema, psoriasis and actinic keratosis.
In addition to a number of leadership positions within clinical development from LEO Pharma and Ferring Pharmaceuticals, Lars was co-founder of the Phase-I unit DanTrials.
Lars is Human Physiologist and PhD from University of Copenhagen and holds a Diploma in Pharmaceutical Drug Development from the University of Basel, Switzerland.
